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Objective: This study was undertaken to evaluate the effect of low molecular weight heparin (LMWH) compared with
unfractionated heparin (UFH) on the rate of occlusion and bleeding during peripheral vascular surgery.
Methods: The study was an open label, prospective, randomized trial, carried out by 20 Swedish surgical and vascular
surgical departments that report to the Swedish Vascular Registry (SWEDVASC). Study subjects included patients
undergoing peripheral vascular procedures, except carotid surgery. Of the 849 patients included, 817 were followed up
to 30 days. LMWH (40 mg of enoxaparin) or UFH (5000 IU heparin) was given intravenously immediately before
clamping. The same formulation in diluted form was used for vascular rinsing. Main outcome measures included patent
reconstruction at day 1, perioperative blood loss, and the percentage of patients requiring protamin. Further, 30-day data
for mortality, repeat operation, and recurrent occlusion are reported.
Results: The mortality rate at 30 days was 2.7%, with no difference between groups. The patency rate at 1 day was 91.2%
to 98.4%, depending on diagnosis and type of reconstruction. No difference was recorded between study groups (0.6 <
P < 1.0). At 30 days the patency rate was 83.1% to 100% (0.2 < P < .9). Median blood loss was 350 mL (interquartile
range [IQR], 200-800 mL) in the LMWH group and 425 mL (IQR, 200-900 mL) in the UFH group (P  .02).
Protamin was given to significantly fewer patients in the LMWH group (P  .001). LMWH was comparable to UFH
during peripheral vascular reconstruction in terms of 1-day and 30-day graft patency, operative blood loss, and
hemorrhagic complications. Protamine was required less often after LMWH. In this randomized trial LMWH was as
effective as UFH in preventing thrombosis without excess bleeding or hemorrhagic complications. (J Vasc Surg 2004;39:
977-84.)It is generally agreed that anticoagulation should be
used during peripheral arterial reconstructions to reduce
the risk for thrombotic occlusion. Common practice is to
use unfractionated heparin (UFH), as either standard or
body weight–adjusted dose, immediately before vascular
clamping, and also to use diluted UFH to flush the vessels
during the procedure.
Low molecular weight heparin (LMWH) is now rou-
tine prophylaxis against postoperative deep vein thrombo-
sis, and has to a great extent replaced UFH to treat venous
thromboembolism. LMWH is also standard treatment in
acute coronary syndromes. The present study was under-
taken to find out whether a single dose of LMWH is
comparable to a corresponding regimen of UFH to prevent
arterial thrombosis during vascular reconstruction and to
compare blood loss with use of the two types of anticoag-
ulation. When the study was planned, background infor-
mation was limited. One small study compared LMWH
and UFH during infrainguinal surgery, and found the same
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doi:10.1016/j.jvs.2004.01.033incidence of graft occlusion in both groups, and compara-
ble effects on coagulation parameters.1 Another random-
ized study conducted during infrainguinal surgery showed
a significantly lower rate of graft thrombosis at 10 days with
LMWH compared with UFH (8% vs 22%).2 In a trial
evaluating the effect of LMWH versus UFH on postoper-
ative deep venous thrombosis during vascular surgery, a
secondary end point was arterial occlusion, which occurred
at the same rate in the two groups.3
The purpose of the present study was to compare the
effects of a fixed dose of either LMWH or UFH just before
arterial clamping during infrarenal aortic or leg revascular-
ization on immediate outcome, patency, and bleeding.
Secondarily, 30-day outcome is reported.
PATIENTS AND METHODS
Between November 2000 and December 2002, 849
patients (507 men, 342 women), ages 40 to 96 years
(median, 74 years) undergoing vascular surgery were in-
cluded in an open randomized trial, and received either 40
mg of enoxaparin (Klexane; Aventis Pharma, Stockholm,
Sweden) intravenously or 5000 IU of UFH (heparin; Leo
Pharma, Malmo¨, Sweden) intravenously, immediately be-
fore arterial clamping. A corresponding heparin formula-
tion was used to irrigate the vessels locally. Randomization
was performed according to the sealed envelope principle,
in blocks of 20 patients per hospital. Twenty hospitals977
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ters were members of SWEDVASC (Swedish Vascular Reg-
istry; see Appendix).
Patients with the following indications for surgery were
included in the study: critical limb ischemia (464 patients),
intermittent claudication (201 patients), abdominal aortic
aneurysm (118 patients), other aneurysm (43 patients),
and other indication (35 patients). Patients undergoing
carotid surgery were excluded.
A bypass procedure was performed in 684 patients,
thromboendarterectomy in 119 patients, thrombectomy in
16 patients, and other procedures in 110 patients.
Postoperative treatment was given at the discretion of
the individual hospital, most commonly aspirin in a dose of
75 mg/d or 160 mg/d, but dextran or LMWH was al-
lowed during the first days after surgery.
The main outcomes measured included patent recon-
struction at 1 and 30 days, perioperative blood loss, and
injection of protamine to stop bleeding. Preoperative co-
agulation parameters (activated partial thromboplastin
time, international normalized ratio) were recorded, as well
as platelet count, which was repeated at day 5 to reveal any
possible heparin-induced thrombocytopenia. Ankle blood
pressure was measured preoperatively and at 30-day follow-
up. The surgeon documented possible thrombi and clots
during the procedure, and made a subjective evaluation of
the technical outcome of the procedure, that is, “success-
ful,” “doubtful,” or “evident occlusion.”
Peroperative bleeding was calculated according to rou-
tine procedure, that is, approximation of the amount of
blood in surgical cloths and suction devices. Protamin was
given at the discretion of the surgeon, indicating that
ongoing bleeding was caused by anticoagulation. Coagu-
lation monitoring was exceptional.
Perioperative assessment of patency was accomplished
with flow measurement in 357 patients, and with only pulse
Table I. Outcome of randomization among 849 patients
Male Female n %
LMWH 270 176 446 52.5
UFH 237 166 403 47.5
Total 507 342 849
LMWH, Low molecular weight heparin; UFH, unfractionated heparin.
Table II. Preoperative treatment
LMWH
(N  446) UFH (N  403)
n % n %
Aspirin 441 62.6 393 61.6
LMWH 435 30.1 394 31.2
UFH 432 5.3 388 4.9
Clopidogrel 435 2.1 389 2.8
Dextran 434 1.8 387 1.6
LMWH, Low molecular weight heparin; UFH, unfractionated heparin.palpation and clinical judgment in the remaining patients.
Postoperative patency was determined according to princi-
ples accepted for SWEDVASC registration, including reg-
ular pulse palpation and ankle blood pressure measure-
ments, and if any doubt existed, the investigator usually
performed duplex ultrasound scanning. The trial did not
specifically ask for the method used.
To ascertain an objective evaluation of possible side
effects, all serious adverse events were reported for assess-
ment to a monitor who was not engaged in the trial.
Statistical analysis. The hypothesis was that LMWH
is as effective as UFH in preventing arterial occlusion. A
power calculation revealed a need for 580 patients to detect
a 5% percent difference if positive outcome is set at 90% (
 0.05;   0.1). The intention was, however, to include
up to 1000 patients. The study was approved by the Ethics
Committee of Lund University, and the Swedish Medical
Products Agency.
Intention to treat analysis and per protocol analysis
were performed. Median and interquartile range (IQR)
were used as summary measures for continuous variables.
Data were treated nonparametrically. Comparisons of me-
dian values in the two groups were performed with the
Mann-Whitney test, and differences in proportions in the
two groups were evaluated with the 2 test. Tables with
one or more expected cell counts below five were analyzed
with the Fisher exact test. Logistic regression was used to
calculate odds ratio in 2 2 tables. Box plots were used to
summarize marginal distributions graphically. This type of
plot has three elements: the box, the whiskers, and the
outliers. The box extends from the lower to the upper
quartile, and the line in the box represents the median.
Whiskers extend to the most extreme observation in each
Table III. Indication for surgery
LMWH UFH
Pn % n %
Critical limb ischemia 237 53.1 227 56.3 .35
Intermittent claudication 114 25.6 87 21.6 .17
Aortic aneurysm 54 12.1 64 15.9 .11
Other aneurysm 29 6.5 14 3.5 .04
Other indication 21 4.7 14 3.5 .37
LMWH, Low molecular weight heparin; UFH, unfractionated heparin.
Table IV. Procedures performed
LMWH UFH
Pn % n %
Bypass (N  684) 354 79.4 330 81.9 .36
Thromboendarterectomy
(N  119)
71 15.9 48 11.9 .10
Thrombectomy (N  16) 7 1.6 9 2.2 .48
Other procedures (N  110) 57 12.8 53 13.2 .87
LMWH, Low molecular weight heparin; UFH, unfractionated heparin.
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IQR; otherwise, they extend to 1.5 times IQR. Outliers are
defined as observations outside the range of the whiskers,
and are presented as individual dots. All tests were two-
sided; P  .05 was regarded as significant. All statistical
calculations were performed with Stata 8.0 (StataCorp,
College Station, Tex).
RESULTS
Of the 849 patients, 817 were followed up to day 30.
Twenty-three patients (2.7%) died, and nine patients were
not followed up for other reasons. The outcome of ran-
domization among the 849 patients is shown in Table I.
There was no difference between the two groups with
regard to sex (P  .6) (Table I) or age (P  .9).
Concomitant preoperative treatment is shown in Table
II. The two treatment groups did not differ in this respect.
Coagulation parameters (activated partial thrombo-
plastin time, P .3; international normalized ratio, P .2)
and platelet count (P  .4) did not differ between the two
groups. The indication for surgery (Table III) did not differ
except in the small group with “other aneurysms.”
Median preoperative ankle blood pressure was 75 mm
Hg (IQR, 50-105 mm Hg) in the LMWH group (n 
435) 80 mm Hg (55-120 mm Hg) in the UFH group (n
370). At 30-day follow-up ankle pressure in the LMWH
group (n  407) had increased, with a median of 55 mm
Fig 1. Scatterplot of postoperative versus preoperativ
Marginal distributions are summarized with box plots.Hg (IQR, 10-85 mm Hg) vs 45 mm Hg (IQR, 10-80) in
the UFH group (n  344). There was no significant
difference between the groups (P  .2). The change in
ankle blood pressure in patients with occlusive disease is
illustrated in Fig 1.
The main types of procedures performed are shown in
Table IV. “Bypass” includes both autologous and synthetic
grafts, all from an aortic tube graft to reconstructions to the
crural arteries. The proportion of procedures did not differ
between the two study groups.
Perioperative blood loss varied between 0 and 15,000
mL, with a median of 350 mL (IQR, 200-800) in the
LMWH group (n  434) and 425 mL (IQR, 200-900) in
the UFH group (n 389) (Fig 2). This median difference
of 75 mL was statistically significant (P .02), although of
limited clinical importance. Bleeding of more than 5000
mL was recorded in six patients in the LMWH group and
five patients in the UFH group. Blood loss in relation to the
procedure and indication for surgery are shown in Tables V
and VI (online only), and Figs 3 and 4 (online only).
Five patients received a further 20 to 40 mg of enox-
aparin because of prolonged operation. In the UFH group
one patient received 2500 IU. Protamin was given to 3% of
patients in the LMWH group (n  440) and 8% in the
UFH group (n  393; P  .001). Patients in the LMWH
received 10 to 50 mg, and patients in the UFH group
le blood pressure in 513 legs (aneurysms excluded).e ank
hepar
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who received 300 mg.
Visible intraoperative thrombosis and clots were re-
corded in 7% in the LMWH group (n  440) and in 8% in
the UFH group (n  393; P  .4).
The immediate outcome of the procedure was regarded
as successful in 91% and 87%, respectively, in the LMWH
and UFH groups. An evident occlusion was recorded in
three patients in each group.
Repeat operations during the first 24 hours were per-
formed in 68 patients, because of occlusion (n  26) and
bleeding (n  36), and were equally distributed between
the two study groups (P  .4). Occlusion occurred in 19
patients in each group (4.3%, LMWH; 4.8%, UFH; P .7).
At 30 days 90.8% (LMWH) and 91% (UFH) of reconstruc-
tions were patent (P .95). Occlusion between days 2 and
30 occurred in 9.2% of the LMWH group and 9.1% of the
UFH group (P  .95). Repeat operations during this
period were performed in 7.2% in the LMWH group and
6.2% percent in the UFH group (P  .6).
Patency data at days 1 and 30 for the respective study
groups, according to type of reconstruction, are shown in
Table VII. Femoropopliteal reconstructions, distal recon-
structions, proximal reconstructions, and extraanatomic
reconstructions did not differ at any time point.
Fig 2. Box plots describe distribution of bleeding in
logarithmic and that 18 bleeding values equal to zero wer
molecular weight heparin [LMWH], 10 unfractionatedPatency with regard to indication for surgery at days 1
and 30 did not differ between the study groups (Table
VIII).
At day 5, platelet counts were performed to exclude
heparin-induced thrombocytopenia. In the LMWH group
(n  334) the median was 257  109/L (IQR, 189-328).
In the UFH group (n  307) corresponding values were
265  109/L (IQR, 205-357; P  .13). There was no
statistically significant difference from preoperative values
(Fig 5). Preoperative median value in the entire patient
group was 270  109/L (IQR, 217-337); 5-day median
value was 262 109/L (IQR, 196-334). Clinically evident
heparin-induced thrombocytopenia was not found. In 11
patients, four in the LMWH group and seven in the UFH
group, platelet count was reduced to less than 100 
109/L, usually subsequent to large perioperative bleeding.
In addition to the above intention-to-treat analysis, a
per protocol analysis was performed, without any diverging
significance levels.
Complications. Two hundred twenty-one complica-
tions were reported during follow-up, 125 in the LMWH
group and 96 in the UFH group. Of these complications,
90 occurred in 76 patients and were reported as possible
severe adverse events, 42 in the LMWH group and 48 in
wo randomized groups. Note that the y-axis scale is
o 10 to make logarithmic transformation possible (8 low
in [UFH]).the t
e set t
above
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LMWH group and 13 in the UFH group.
Bleeding with possible causal relationship to the study
drugs was reported in 24 patients given LMWH and 20
given UFH; one patient in each group died. Repeat oper-
ation to treat bleeding was performed in 19 patients given
LMWH and 17 patients given UFH. In four patients in the
UFH group, bleeding was accompanied by myocardial
infarction. One spinal hematoma was reported, in a patient
in the UFH group who was given epidural anesthesia. The
clinical significance of hemorrhage and possible secondary
complications was evaluated with a scoring system ranging
from 1 (mild) to 5 (fatal). The average severity score was
2.8 in the LMWH group and 3.4 in the UFH group (P 
NS). Postoperative bleeding occurred in five patients (three
given LMWH, two given UFH) of the 20 patients who
were given preoperative treatment with clopidogrel, com-
pared with 39 patients with postoperative bleeding of 790
not given clopidogrel (P  .001; odds ratio 6.4; 95%
confidence interval, 2.2-19). Similar comparisons for pre-
operative treatment with aspirin or LMWH did not disclose
significantly increased risk for postoperative bleeding.
DISCUSSION
On the basis that LMWH is effective in prevention of
deep venous thrombosis after vascular surgery and after
general surgery4 and that LMWH is useful also to prevent
Table VII. Patency at 1 and 30 days
Number of
evaluated
procedures
at 24 hours
24-hour
Femoropopliteal reconstruction ak
and bk (N  313)
176 LMWH
137 UFH
Distal reconstruction (N  170) 79 LMWH
91 UFH
Proximal reconstruction (N  130) 66 LMWH
64 UFH
Extra-anatomic reconstruction
(ax-fem; fem-fem) (N  62)
28 LMWH
34 UFH
*Fisher exact test.
LMWH, Low molecular weight heparin; UFH, unfractionated heparin; ak,
Table VIII. Patency with regard to indication for surgery
Number of
evaluated
procedures
at 24 hours
24-hour patency
n
Critical limb ischemia 236 LMWH 223
224 UFH 209
Intermittent claudication 113 LMWH 109
85 UFH 82
Aortic aneurysm 54 LMWH 53
64 UFH 63
*Fisher exact test.
LMWH, Low molecular weight heparin; UFH, unfractionated heparin.arterial thrombi, both clinically5 and experimentally,6 we
compared a single dose of LMWH during vascular surgery
before vascular clamping with the same regimen using
UFH. Further, the better bioavailability and longer plasma
half-life of LMWH would be of benefit. Only a few pro-
spective, randomized studies have compared LMWH and
UFH in this regard. In the study by Samama et al,2 201
patients were randomized to receive either an intravenous
bolus dose of LMWH or UFH at a dose related to body
weight. This regimen was continued postoperatively, and
graft patency was assessed at 10 days. Graft thrombosis
occurred significantly less often in the LMWH group (8% vs
22%). Hingorani et al7 retrospectively analyzed 330 pa-
tients receiving either UFH plus warfarin or subcutaneous
LMWH plus warfarin. They concluded that use of LMWH
is safe, and in this series it also reduced the postoperative
length of stay, compared with the UFH group. Paramo et
al8 reported a prospective study of a small group of patients,
and found an extremely low rate of graft thrombosis (0% in
the LMWH group, 4% in the UFH group, occurring only
in femorodistal bypass procedures).
The present study is the only one evaluating in a larger
group of patients whether LMWH can be used instead of
UFH during surgery. Ninety-five percent of patients ran-
domized in this study were followed up at 30 days. Mor-
tality at 30 days was low, although critical ischemia was the
indication for surgery in almost 60% of patients. Nonavail-
ncy
P
Number of
evaluated
procedures
at 30 days
30-day patency
P% n %
96.0 .6 174 LMWH 156 89.7 .3
97.1 134 UFH 115 85.8
92.4 .8 77 LMWH 64 83.1 .4
91.2 87 UFH 76 87.4
97.0 1.0* 65 LMWH 60 92.3 .2*
96.9 63 UFH 62 98.4
92.9 1.0* 28 LMWH 24 85.7 .2*
94.1 33 UFH 32 97.0
knee; bk, below knee; ax-fem, axillofemoral; fem-fem, femorofemoral.
and 30 days
P
Number of
evaluated
procedures
at 30 days
30-day patency
Pn %
0.6 230 LMWH 200 87.0 0.9
216 UFH 189 87.5
1.0* 113 LMWH 106 93.8 0.3
85 UFH 76 89.4
1.0* 54 LMWH 52 96.3 0.2*
63 UFH 63 100.0pate
n
169
133
73
83
64
62
26
32at 1
%
94.5
93.3
96.5
96.5
98.1
98.4
versu
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ankle blood pressure, bleeding, and occlusion rates at in-
clusion and to 24 hours of follow-up. At 30 days ankle
blood pressure measurements were missing in 12%, and
occlusion rates in 5%. The platelet count at 5 days was
recorded for about 75% of patients.
The outcome at 30-day follow-up depended not only
on the antithrombotic regimen during surgery but also on
the postoperative treatment, which may have differed be-
tween centers. The study did not record this treatment, but
the variation between Swedish vascular centers is limited,
and it is likely that most patients received LMWH in the
first postoperative days, and subsequently aspirin in a dose
of 75 to 160 mg/d. Conclusions regarding the 30-day
outcome are therefore secondary in this trial. The immedi-
ate outcome regarding occlusion and bleeding is, however,
an effect of the perioperative regimen. The two groups
were comparable with regard to patient demographic data,
indications for surgery, and procedures performed. In the
first 24 hours the rate of occlusion did not differ, either in
the entire treatment group or when analyzed according to
surgical procedures or indications. Blood loss during sur-
gery was slightly less in the LMWH group. The median
difference of 75 mL was statistically significant, but the
clinical benefit was less important. Outliers, bleeding more
than 5000 mL, did not differ between groups. Protamin
was administered in significantly fewer patients in the
LMWH group. As appears, protamin was used to a limited
Fig 5. Scatterplot of day 5 platelet countextent, which is customary in Sweden. Only small doses are
given, and only when the surgeon finds that ongoing
bleeding may depend on the anticoagulant given. The
finding is, however, interesting, because it emphasizes that
the role of protamin is limited when anticoagulation is
accomplished with LMWH. We compared 5000 IU of
UFH and 40 mg of enoxaparin, which seemed to be
equipotent according to effect. In a dose-finding study,
Kujath et al9 evaluated four dose regimens, and found that
half of the therapeutic dose of reviparin was effective and
caused less bleeding. We selected the “higher” prophylactic
dose (40 mg) of enoxaparin, and achieved comparable
results. It is important to state that various LMWH formu-
lations may differ in some respects.
At 30 days there were no differences between the study
groups with regard to the indications for surgery or the
procedures performed.
Our results differ from those of Samama et al,2 achiev-
ing significantly fewer occlusions after 10 days in the
LMWH group. Their study design differed, however, in
that they used LMWH versus UFH daily after surgery until
day 10. Furthermore, only femorodistal reconstructions
were included. In contrast, the study by Farkas et al3
reported the same rate of occlusion in the LMWH and
UFH groups at 7 to 10 days postoperative.
The clinical significance of the reported hemorrhagic
complications in our series did not differ between groups.
Only one spinal hematoma was noted in the entire series, in
s preoperative platelet count (n  618).
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not consider the type of anesthesia used, there is no infor-
mation on the rate of epidural versus general anesthesia.
The combination of preoperative clopidogrel and UFH
or LMWH appears to induce a significant risk for postop-
erative bleeding.
Clinically evident heparin-induced thrombocytopenia
was not recorded in any of the 641 patients examined at day
5. In a series of 665 patients, half of whom received UFH
and half LMWH as prophylaxis after hip surgery, thrombo-
cytopenia occurred in 2.7% of patients given UFH, but in
no patient given LMWH.10 Blood sampling in this trial was
performed from day 5 of heparin prophylaxis. The obvious
difference between the two series is the short-lasting hepa-
rin treatment in our trial. Our study compares platelet
count preoperatively and 5 days postoperatively, which
implies that patients with thrombocytopenia induced by
perioperative bleeding without any relation to the admin-
istration of heparin are recorded.
From a practical point of view, hospitals may benefit
from using LMWH for all indications when heparin is
required. Taking into consideration that LMWH has re-
placed UFH for the treatment of deep venous thrombosis
and pulmonary embolism, and that it is frequently used
postoperatively after vascular procedures, the use of this
substance also during vascular surgery seems relevant.
The issue of cost may be mentioned. List prices indicate
that LMWH is more expensive, but commonly bulk prices
exist for purchase of large volumes and other drugs from
the same manufacturer. Although it is likely that UFH may
be slightly less expensive than LMWH, calculated from
direct costs, indirect costs may increase if UFH must be
stored for only a single indication. The value of using a
better defined drug with predictable effects should also be
considered.
In conclusion, enoxaparin is safe and easy to use, and
adequately prevents early thrombotic occlusions. It should
be emphasized that this study evaluated only enoxaparin,
and it is not possible to conclude that all LMWHs exert the
same effect, although this may well be the case.
We thank Janet Johansson, Secretary at the Trial Office,
for efficient handling of communication and for support of
the trialists.
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